Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000610679 | SCV000727308 | likely benign | not specified | 2018-02-28 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV001868072 | SCV002114649 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2023-08-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003362862 | SCV004053807 | uncertain significance | Cardiovascular phenotype | 2023-07-21 | criteria provided, single submitter | clinical testing | The p.T373A variant (also known as c.1117A>G), located in coding exon 8 of the JAG1 gene, results from an A to G substitution at nucleotide position 1117. The threonine at codon 373 is replaced by alanine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |